Bofanglutide
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 24 mg GZR18 group | n/r | n/r | n/r | n/r | n/r |
| 36 mg GZR18 group | n/r | n/r | n/r | n/r | n/r |
| 48 mg GZR18 group | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.